Design Therapeutics (DSGN) Revenue (2020)
Design Therapeutics (DSGN) reported Revenue of $33000.0 for Q4 2020, up 65.0% sequentially from $20000.0 in Q3 2020.
Design Therapeutics (DSGN) Revenue (2020) Analysis & Trends
Design Therapeutics (DSGN) has 1 years of Revenue data on file, last reported at $33000.0 in Q4 2020.
- For the quarter ending Q4 2020, Revenue changed N/A year-over-year to $33000.0; the trailing twelve-month figure through Dec 2020 stood at $226000.0 (changed N/A YoY), and the FY2020 full-year result was $226000.0, changed N/A from the prior year.
- Revenue rose to $33000.0 in Q4 2020, from $20000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $142000.0 in Q1 2020 to a low of $20000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Design Therapeutics | 725.54 Mn | 502.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 33,000.00 |
| Sep 30, 2020 | 20,000.00 |
| Jun 30, 2020 | 31,000.00 |
| Mar 31, 2020 | 142,000.00 |